Drug intelligence / Profile preview

SAB-162

Development stage: Discontinued
Lead developer: SAB Biotherapeutics

Overview

SAB-162 is an investigational therapeutic initially developed by SAB Biotherapeutics. It appears related to neoplasms, though publicly accessible information about the molecular type, mechanism of action, or targeted indication beyond "neoplasms" is not available. The global highest R&D status for SAB-162 is listed as discontinued. No additional mechanistic or clinical development details are public[5].

Targets

EGFR T790M (Epidermal growth factor receptor T790M mutant)EGFRvIII (Epidermal growth factor receptor variant III)

Beyond the preview

Go deeper on SAB-162.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SAB-162.

Explore the full profile